HR Execs on the Move

Invitae

www.invitae.com

 
Invitae is a leader in medical genetic testing, driving genetic information into mainstream medicine to improve healthcare for billions of people. Invitae is aggregating the world`s medical genetic tests into a single service with higher quality, faster turnaround time, and lower prices. By driving down the cost of genetic testing we make it affordable and accessible to everyone who can benefit. Why medical genetics? Within each of us lies information coded in our DNA that can transform our health. Unlocking those answers to make medicine more personalized requires highly specialized, multidisciplinary collaboration. Our platform is setting the standard for the ...
  • Number of Employees: 1K-5K
  • Annual Revenue: > $1 Billion
  • www.invitae.com
  • 1400, 16th Street
    San Francisco, CA USA 94103
  • Phone: 415.374.7782

Executives

Name Title Contact Details
Ana Schrank
 Chief Financial Officer Profile
Robert Dickey
 Interim Chief Financial Officer Profile
Robert Dickey
 Interim Chief Financial Officer Profile
Matt Willmon
 Vice President, Total Rewards Profile
Eric Olivares
 Head of Research And Development Profile

Similar Companies

Affitech USA

Affitech USA is a Walnut Creek, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Hoffmann-La Roche

Hoffmann-La Roche Inc. (Roche), based in Nutley, N.J., is the U.S. prescription drug unit of the Roche Group, a leading research-based health care enterprise that ranks among the world's leaders in pharmaceuticals, diagnostics and vitamins. Roche

Modis Therapeutics

Modis Therapeutics is a biopharmaceutical company focused on developing disease-modifying therapies for rare genetic diseases with high unmet medical need.

SpIntellx

See More. Know More. Power Precision Pathology.

Lineage Cell

Lineage Cell Therapeutics is a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs. Lineage`s programs are based on its proprietary cell-based therapy platform and associated development and manufacturing capabilities. With this platform Lineage develops and manufactures specialized, terminally-differentiated human cells from its pluripotent and progenitor cell starting materials. These differentiated cells are developed either to replace or support cells that are dysfunctional or absent due to degenerative disease or traumatic injury or administered as a means of helping the body mount an effective immune response to cancer. Lineage`s clinical assets include (i) OpRegen®, a retinal pigment epithelium transplant therapy in Phase I/IIa development for the treatment of dry age-related macular degeneration, a leading cause of blindness in the developed world; (ii) OPC1, an oligodendrocyte progenitor cell therapy in Phase I/IIa development for the treatment of acute spinal cord injuries; and (iii) VAC2, an allogeneic cancer immunotherapy of antigen-presenting dendritic cells currently in Phase I development for the treatment of non-small cell lung cancer.